BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 01:44:15 09/02/2026 pm IST			5-day change	1st Jan Change
319.30 ^SEK	+4.07%		-3.82%	-1.29%

12:25pm	China Grants Priority Review to BioArctic's Subcutaneous Autoinjector to Treat Early Alzheimer's	MT
11:22am	Priority Review in China for Subcutaneous Leqembi Treatment	FW

EU Committee Backs BioArctic's Exidavnemab for Multiple System Atrophy in EU

Published on 05/22/2025 at 08:10 pm IST

MT Newswires

Latest news about BioArctic AB

12:25pm	China Grants Priority Review to BioArctic's Subcutaneous Autoinjector to Treat Early Alzheimer's	MT
11:22am	Priority Review in China for Subcutaneous Leqembi Treatment	FW
06/02	Bioarctic reports Q4 sales of Leqembi at yen 20.7 billion	RE
06/02	Bioarctic's Royalty from Leqembi Sales Rises 31 Percent in Fourth Quarter	FW
06/02	Bioarctic: Leqembi Sales Reached 20.7 Billion Yen in the Fourth Quarter of 2025	FW
05/02	Goldman Sachs Raises Price Target for Bioarctic to SEK 346 (339), Reiterates Buy - BN	FW
04/02	Nordea Raises Target Price for Bioarctic to 236 Kronor (230), Reiterates Sell	FW
27/01	Bioarctic Partner Seeks EU Approval for Expanded Maintenance Therapy with Leqembi	FW
27/01	BioArctic, Eisai Files Marketing Authorization Variation for Early Alzheimer's Disease Treatment in EU	MT
27/01	Eisai submits marketing authorisation variation to EMA	RE
27/01	Eisai submits marketing authorisation variation to EMA for intravenous maintenance dosing with Leqembi	RE
27/01	Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®?	CI
26/01	Stockholm Bullets - Note Rises on Quarterly Report	FW
26/01	FDA Grants Priority Review to Leqembi Iqlik as Subcutaneous Initiation Therapy – Decision Expected by May 24	FW
26/01	US FDA Places BioArctic Partner Eisai's Leqembi Iqlik Under Priority Review	MT
26/01	BioArctic says FDA grants priority review to Leqembi Iqlik supplemental application	RE
26/01	Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review	CI
15/01	19 Stocks Reach New 52-Week Highs Today on the Stockholm Stock Exchange	FW
14/01	Biogen CEO: At-Home Alzheimer's Treatment Could Give Edge Over Lilly's Version - BN	FW
07/01	Stockholm Bullets - Strong Opening Surge, Munters Weighed Down by Nvidia Statement	FW
07/01	Bioarctic's Partner Submits Application for Subcutaneous Leqembi Treatment Approval in China	FW
06/01	BioArctic's Leqembi Subcutaneous Formulation BLA Lands Acceptance in China	MT
05/01	Bioarctic Likely to Begin Dividend Payments in 2027 - Di	FW
19/12	Saab Rises on New Orders, OMXS30 Index Up 0.5 Percent	FW
19/12	Koprek Lifts Axfood, OMXS30 Index Up 0.1 Percent	FW

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Employees

122

Sector

Biotechnology & Medical Research

Calendar

18/02 - Q4 2025 Earnings Release

More about the company